Sign up Australia
Proactive Investors - Run By Investors For Investors

Eli Lilly raises full-year earnings guidance; flags plans to float Elanco Animal Health

"Lilly delivered strong results once more in the second quarter in terms of operational performance, pipeline advancements and strategic objectives," said David Ricks, the company's chairman and CEO.
IPO
Eli Illy is planning an IPO for its animal health division

Shares in Eli Lilly and Co (NYSE:LLY) were wanted in pre-market trading after the drugs-maker topped earnings expectations with its second quarter results.

The shares were up more than 5% at US$93.39 in screen-based trading after the group said it expects full-year earnings per share to be in the range of US$5.40 – US$5.50, with both ends of the range being well above the median forecast of US$5.15 from analysts who follow the stock.

READ Eli Lilly 1Q earnings beat Street, but FDA delivers disappointing recommendation for new arthritis drug

Underlying second quarter earnings per share of US$1.50 comfortably beat the consensus forecast of US$1.30.

The company posted a net loss of US$259.9mln, versus a profit of US$1.01bn in the corresponding period of last year but this was after one-off charges including a hefty restructuring charge of US$3bn.

Revenue rose to US$6.36bn, up 9% year-on-year and ahead of the consensus estimate of US$6.05bn.

"The increase in our worldwide revenue was fueled by volume growth of our new medicines, while we also maintained a keen focus on containing costs and improving productivity,” declared David Ricks, the chairman and chief executive officer of Lilly.

“Our pipeline continued to demonstrate our commitment to scientific innovation, highlighted by forward progress for key molecules, several positive late-stage data readouts and the addition of promising new assets through business development,” he added.

In a separate announcement, the company said it would hive off up to 20% of its Elanco Animal Health unit and float it on the stock exchange.

Lilly plans to divest its remaining ownership through a tax-efficient transaction.

"Based on our strategic review, we concluded that after-tax value for Lilly shareholders would be maximized by pursuing an initial public offering of Elanco," Ricks said.

"We believe this will allow Elanco to efficiently deploy its resources to those growth opportunities that best serve its customers. In addition, this will provide Lilly even greater focus on the human pharmaceutical business to pursue our purpose of creating life-changing medicines for patients," he added.

Established in 1954, Elanco provides products and knowledge services to improve animal health and food-animal production in more than 70 countries.

In a separate announcement, the company said it would hive off up to 20% of its Elanco Animal Health unit and float it on the stock exchange.

Lilly plans to divest its remaining ownership through a tax-efficient transaction.

"Based on our strategic review, we concluded that after-tax value for Lilly shareholders would be maximized by pursuing an initial public offering of Elanco," Ricks said.

"We believe this will allow Elanco to efficiently deploy its resources to those growth opportunities that best serve its customers. In addition, this will provide Lilly even greater focus on the human pharmaceutical business to pursue our purpose of creating life-changing medicines for patients," he added.

Established in 1954, Elanco provides products and knowledge services to improve animal health and food-animal production in more than 70 countries.

View full LLY profile View Profile

Eli Lilly Timeline

Related Articles

Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use